{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T22:35:43Z","timestamp":1772836543774,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1124\/jpet.122.001440","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T16:49:15Z","timestamp":1669308555000},"page":"406-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Effects of Dual GLP-1\/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis"],"prefix":"10.1016","volume":"384","author":[{"given":"Ashref","family":"Kayed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1844-3294","authenticated-orcid":false,"given":"Simone Anna","family":"Melander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suheb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim Vietz","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten Asser","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001440_bib1","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/S0140-6736(18)30726-8","article-title":"MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study","volume":"391","author":"Ambery","year":"2018","journal-title":"Lancet"},{"key":"10.1124\/jpet.122.001440_bib2","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1111\/bcp.13688","article-title":"MEDI0382, a GLP-1\/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study","volume":"84","author":"Ambery","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.122.001440_bib3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.122.001440_bib4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat Metab"},{"key":"10.1124\/jpet.122.001440_bib5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/bip.22072","article-title":"Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents","volume":"98","author":"Day","year":"2012","journal-title":"Biopolymers"},{"key":"10.1124\/jpet.122.001440_bib6","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat Chem Biol"},{"key":"10.1124\/jpet.122.001440_bib7","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1111\/dom.13212","article-title":"Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates","volume":"20","author":"Elvert","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.122.001440_bib8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0031-9384(83)90207-X","article-title":"Selective hepatic vagotomy blocks pancreatic glucagon\u2019s satiety effect","volume":"31","author":"Geary","year":"1983","journal-title":"Physiol Behav"},{"key":"10.1124\/jpet.122.001440_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.peptides.2018.10.013","article-title":"Glucagon-related peptides from phylogenetically ancient fish reveal new approaches to the development of dual GCGR and GLP1R agonists for type 2 diabetes therapy","volume":"110","author":"Graham","year":"2018","journal-title":"Peptides"},{"key":"10.1124\/jpet.122.001440_bib10","doi-asserted-by":"crossref","first-page":"E821","DOI":"10.1152\/ajpendo.00514.2015","article-title":"KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight","volume":"310","author":"Gydesen","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1124\/jpet.122.001440_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0031-9384(85)90074-5","article-title":"Increase of food intake induced by glucagon in the rat","volume":"34","author":"Hell","year":"1985","journal-title":"Physiol Behav"},{"key":"10.1124\/jpet.122.001440_bib14","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/dom.12735","article-title":"Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates","volume":"18","author":"Henderson","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.122.001440_bib15","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1517\/14712598.2010.526104","article-title":"Oral salmon calcitonin\u2013pharmacology in osteoporosis","volume":"10","author":"Henriksen","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1124\/jpet.122.001440_bib16","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1124\/jpet.122.001440_bib17","unstructured":"Jung SY, Park YJ, Kim JK, Lee JS, Lee YM, Kim YH, Kang JH, Trautmann M, Hompesch M, and Kwon SC, (2014) Lipolytic and insulinotropic effects of HM12525A, a novel long-acting GLP-1\/glucagon dual agonist. Presented at EASH Meeting, 2014. Availible at: https:\/\/www.easd.org\/media-centre\/home.html#!resources\/lipolytic-and- insulinotropic-effects-of-hm12525a-a-novel-long-acting-glp-1-glucagon-dual- agonist--2 (Accessed 91 dec 2022)."},{"key":"10.1124\/jpet.122.001440_bib18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13075-019-1819-9","article-title":"Combining naproxen and a dual amylin and calcitonin receptor agonist improves pain and structural outcomes in the collagen-induced arthritis rat model","volume":"21","author":"Katri","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 1","key":"10.1124\/jpet.122.001440_bib19","doi-asserted-by":"crossref","first-page":"991-P","DOI":"10.2337\/db19-991-P","article-title":"991-P: Potential of a Novel Long-Acting Glucagon Analog, HM15136, for the Treatment of Obesity","volume":"68","author":"Kim","year":"2019","journal-title":"Diabetes"},{"key":"10.1124\/jpet.122.001440_bib20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1872-034X.2011.00946.x","article-title":"Enzyme-linked immunosorbent serum assay specific for the 7S domain of Collagen Type IV (P4NP 7S): A marker related to the extracellular matrix remodeling during liver fibrogenesis","volume":"42","author":"Leeming","year":"2012","journal-title":"Hepatol Res"},{"key":"10.1124\/jpet.122.001440_bib21","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.aohep.2019.04.011","article-title":"The GLP-1 analog liraglutide attenuates acute liver injury in mice","volume":"18","author":"Milani","year":"2019","journal-title":"Ann Hepatol"},{"key":"10.1124\/jpet.122.001440_bib22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1152\/physrev.00025.2016","article-title":"The New Biology and Pharmacology of Glucagon","volume":"97","author":"M\u00fcller","year":"2017","journal-title":"Physiol Rev"},{"key":"10.1124\/jpet.122.001440_bib23","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1210\/jcem-64-5-896","article-title":"Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency","volume":"64","author":"Nair","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/jpet.122.001440_bib2021","doi-asserted-by":"crossref","DOI":"10.1002\/pep2.24221","article-title":"Design and characterization of a surfactant-conjugated, long-acting, balanced GLP -1\/glucagon receptor dual agonist","volume":"113","author":"Nestor","year":"2021","journal-title":"Peptide Science"},{"key":"10.1124\/jpet.122.001440_bib7262723","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-10577-2","article-title":"Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis","volume":"12","author":"Nestor","year":"2022","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001440_bib24","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/dom.12713","article-title":"Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice","volume":"18","author":"O\u2019Harte","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.122.001440_bib473336","article-title":"Acylated Glucagon Analogue","author":"Riber","year":"2018","journal-title":"US Patent 15\/566,338. 2018"},{"key":"10.1124\/jpet.122.001440_bib25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/dom.12585","article-title":"Glucagon increases energy expenditure independently of brown adipose tissue activation in humans","volume":"18","author":"Salem","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.122.001440_bib26","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001440_bib27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.peptides.2018.04.008","article-title":"Oxyntomodulin analogue increases energy expenditure via the glucagon receptor","volume":"104","author":"Scott","year":"2018","journal-title":"Peptides"},{"key":"10.1124\/jpet.122.001440_bib28","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2174\/092986730611220401164504","article-title":"Calcitonin","volume":"6","author":"Sexton","year":"1999","journal-title":"Curr Med Chem"},{"key":"10.1124\/jpet.122.001440_bib29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/dom.13494","article-title":"A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials","volume":"21","author":"Tillner","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.122.001440_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524004166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524004166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:28:09Z","timestamp":1739971689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524004166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0022356524004166"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001440","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effects of Dual GLP-1\/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}